newsfilter
← Latest News
Business Wire·

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

– Initial Phase 2 data presented for ADCETRIS in combination with immunotherapy pembrolizumab in metastatic non-small cell lung cancer and metastatic cutaneous melanoma – – Preclinical data presented for novel